Sirna Therapeutics to Join the NASDAQ Biotechnology Index
News Nov 23, 2005
Sirna Therapeutics, Inc. has announced that the company was added to the NASDAQ Biotechnology Index effective at the open of the U.S. markets on 21st Nov.
"We are extremely pleased to be included among the leading biotechnology and pharmaceutical companies listed on the NASDAQ Biotechnology Index," said Howard W. Robin, Chief Executive Officer of Sirna Therapeutics.
"Our addition to this Index further supports the important achievements Sirna has made in the field of RNA interference."
"Our company is at the forefront of RNAi-based therapeutic research and development having been the first company to present human clinical trial data on a short interfering RNA compound."
"We will continue to pioneer the development of RNAi-based therapeutics and look forward to bringing this novel class of drugs to patients in need."
Launched in 1993, the NASDAQ Biotechnology Index includes securities that are classified according to the FTSE Global Classification System™ as biotechnology or pharmaceutical, and is ranked on a semi-annual basis in May and November.
All securities are listed on the NASDAQ National Market® and meet minimum requirements for market value, average daily share volume and seasoning as a public company.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.